Eli Lilly and Company partnered with Resilience to invest $750 million in U.S. manufacturing capacity. This capital will expand domestic production for the company’s diabetes and obesity treatments.
The collaboration aims to improve supply chain reliability for American patients. The initiative is expected to create new jobs within the U.S. biomanufacturing sector.
This expansion specifically targets the high-demand GLP-1 drug franchise. The investment allows Eli Lilly to meet surging demand and solidify its position against market competitors.